
Tirzepatide
Tirzepatide (Mounjaro, Zepbound)
Strongfat_lossmetabolic
Community score3.50 reviews · 0 tracking
FDA-approved (Mounjaro for type 2 diabetes, Zepbound for chronic weight management). A dual GIP/GLP-1 agonist with the largest weight-loss effect of any approved pharmaceutical, averaging 21% reduction at 15 mg weekly in SURMOUNT-1. Strong evidence base.
For research and personal log purposes. peptidio does not sell, ship, prescribe, or endorse any peptide for the prevention, treatment, or cure of any condition.